Kurma Partners invests in OxThera
Kurma Partners’s Biofund II, the first venture capital fund dedicated to financing innovation in the rare diseases space, has made its maiden EUR7.5 million investment in Oxthera, a Stockholm-based biopharmaceutical company.
OxThera is currently conducting a placebo-controlled clinical trial with Oxabact in patients with primary hyperoxaluria at seven clinical sites in three countries.
Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death.
Rémi Droller, managing partner of Kurma Partners, who joins the board of directors of OxThera, says: “This first investment of Kurma Biofund II, is fully consistent with our investment strategy to support business innovation for Life Sciences in Europe, in a context where the development of new treatments and diagnostic tools for rare diseases is increasingly sought-after by industrialists seeking therapeutic innovation.”
- By Category
- News from other sites
- Special Reports
- Partner events